Alpha.santitrypsin was measured in 5-day faecal collections from patients with colorectal cancer or adenomatous polyps and a symptomatic control group. Collections were homogenized and lyophilized prior to measurement of lXI-antitrypsin by radial immuno-diffusion. Colorectal cancer dry weight concentrations were significantly higher than the symptomatic control results, with 570/0 having results greater than 95% normal values of this control group. There was no significant difference between adenomatous polyp dry weight concentrations and symptomatic control results. Wet weight concentrations were calculated from wet/dry ratios. Colorectal cancer wet weight concentrations were significantly higher than symptomatic control results with 48% having results greater than 95% normal values of this control group. Alpha.vantitrypsin was also measured in non-lyophilized samples from an asymptomatic control group (n = 39). Colorectal cancer wet weight concentrations were significantly higher than asymptomatic control results, with 62% having results greater than 95% normal values of this control group. Faecal lXI-antitrypsin measurement deserves further assessment for use in detecting colorectal cancer.
Additional key phrases: occult blood; protein-losing enteropathy; colorectalneoplasms
Faecal occult blood tests have been proposed as a screening test for the detection of colorectal cancer. I The most commonly used test in population studies is Haemoccult (Smith Kline Diagnostics, Sunnyvale, CA, USA), which has proved to be of value in the detection of asymptomatic colorectal cancers.P It is inherently inefficient as many colorectal cancers do not bleed," especially the polypoidal and welldifferentiated cancers. ' The benefits of screening programmes for colorectal cancer remain uncertain and improved screening tests are required. 6 Alpha-antitrypsin is a serum protease inhibitor which is synthesized mainly in the liver, but also in other sites, including intestinal epithelial cells and macrophages. It is also produced by the colorectal cancer cell line CAC02. 7 The measurement of faecal lXI-antitrypsin was originally developed as a test for protein-losing enteropathy. 8 Faecal lXI-antitrypsin clearance using lyophilized Correspondence: Dr A Moran, Department of Gastroenterology, East Birmingham Hospital, Bordesley Green East, Birmingham B9 SST, UK. 28 samples is often used for detecting protein-losing enteropathy and some studies have suggested that only a random faecal sample is needed.v!'
Alpha.-antitrypsin appears relatively resistant to degradation in faecal samples'? although proteolytic fragments" and a number of molecular forms'? have been detected. Levels may be raised in upper gastro-intestinal diseases, although degradation of lXI-antitrypsin will occur in acidic media." Protein-losing enteropathy is commonly caused by those diseases in which occult blood loss occurs, 16 which indicates that this test could be used in situations where faecal occult blood tests would normally be applied. Enteric protein loss in these conditions is unlikely to relate purely to blood loss and may be due to mucosal oedema and inflammation. The increased protein loss may be due to increased epithelial cell turnover and damaged epithelial tight junctions.
Since faecal lXI-antitrypsin measurement may be able to detect colorectal cancer by both increased blood loss and protein loss due to mucosal oedema and inflammation, we have investigated patients with colorectal cancer or adenomatous polyps and a symptomatic and asymptomatic control group. We used 5-day collections of faeces to study the relationship between transit time and faecal ai-antitrypsin concentration.
PATIENTS AND METHODS

Patients
Patients with colorectal cancer or adenomatous polyps and a symptomatic control group were recruited from the surgical out-patients clinic (Dudley Road Hospital, Birmingham, UK). This control group comprised patients with nonspecific abdominal symptoms, all of whom underwent rigid sigmoidoscopy and double contrast barium enema or colonoscopy. An asymptomatic control group without known causes of proteinlosing enteropathy was also recruited from hospital staff, medical out-patients (East Birmingham Hospital, Birmingham, UK) and a well person clinic. All the surgical out-patient group had baseline liver function tests performed (serum aspartate aminotransferase, bilirubin and alkaline phosphatase), the results of which were all within normal limits. None of the patients with cancer had symptoms or radiological evidence of obstruction.
Methods
Surgical out-patients were recruited following diagnosis (and prior to resection of polyps or cancers) and provided S-day faecal collections at home with all specimens being immediately stored at -20°C in portable freezers. A mouth-to-anus transit time was measured using radio-opaque markers (Portex UK Ltd, Hythe, UK).I? The faecal collections were thawed and diluted with five times the faecal weight of deionized ice-cold water (milliQ, Millipore, Watford, UK) and homogenization was achieved using a Stomacher (Seward, London, UK) for 20 min. Ten millilitre aliquots were lyophilized and stored under vacuum. The asymptomatic control group provided single stool samples that were stored at -20°C after collection and were not lyophilized.
Lyophilized samples of 100 mg were diluted to a volume of 5 mL and non-lyophilized samples of 2 g were diluted to a volume of 10 mL in a cationic detergent (500 mmol/L NaCl, 100 mmol/L CaCI 2 , and 7 mL/L lauryl trimethylammonium bromide). 18 The samples were then vortex mixed and centrifuged at 500g for 20 min. Faecal ai-antitrypsin was measured by radial immunodiffusion using goat antiserum to human
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aI-antitrypsin and serum calibrators.P Wet faecal weight ai-antitrypsin values were calculated from wet/dry weight ratios. Samples were analysed in a blinded fashion using coded containers and results correlated to diagnosis in the presence of an independent observer. Lauryl trimethyl ammonium bromide, goat antiserum to human ai-antitrypsin and aI-antitrypsin calibrators were obtained from the Sigma Chemical Company (Poole, UK).
Statistics
A two-tailed Mann-Whitney Utest was used for analysis of continuous variables. Correlation was measured using Spearman's rank correlation test. Statistical significance was taken as P< 0·05. Ninety-five per cent reference limits for dry and wet weight faecal aI-antitrypsin were calculated from mean values ± I . 96 standard deviations.
Ethical approval was obtained from the Ethical Committees of West Birmingham and East Birmingham Health Authorities.
RESULTS
Ninety-one patients were recruited, 21 with colorectal cancer (median age, range: 68, 47-79 years); 10 with adenomatous polyps (67, 27-76 years); 21 symptomatic control patients (68, 46-81 years) and 39 asymptomatic control patients (33, 19-62 years). Data from patients with colorectal cancer, polyps and the symptomatic control group are shown in Tables 1-3, respectively. The polyps in the colorectal adenoma group varied in size from O·5-2 ern, The dry and wet faecal weight aI-antitrypsin values from the three groups are shown in Figs I and 2, respectively.
In the cancer group there were no significant relationships between age, sex, or site of cancer and either dry or wet faecal weight ai-antitrypsin concentrations. Transit times were slower in the cancer group compared to the symptomatic control group (P = O·(02), but there was no significant difference between the adenoma group and the symptomatic control group. There was no significant correlation between transit times and dry or wet faecal aI-antitrypsin in any of the three groups. The daily wet faecal weights in the cancer group (median, range: 93· 5, 27' 0-205 . 7 g) did not significantly correlate with dry or wet faecal weight faecal aI-antitrypsin concentration. 
Dry faecal weight arantitrypsin concentrations
These concentrations were significantly increased in the colorectal cancer group compared to the symptomatic control group (P=O'OO4); 12 of the 21 cancer patients (57%) had values greater than the symptomatic control group upper limit of 3· 3 mg/g dry weight (Fig. 1 ). There was no significant difference between dry faecal weight concentrations in the adenoma group compared to the symptomatic control group, although two adenoma patients had values greater than 3'3 mg/g.
Wet faecal weight at-antitrypsin concentrations
These were increased in the colorectal cancer group compared to the symptomatic control group (P= O'03); 10 of the 21 cancer patients (48%) had values greater than the symptomatic control group upper limit of O'74 mg/g (Fig. 2) . Wet faecal weight ai-antitrypsin concentrations were also increased in the colorectal cancer group compared to the asymptomatic control group (P<O·OOI); 13 of the 21 cancer patients (620/0) had values greater than this control group upper limit of 0·35 mg/g. There was no significant difference between wet weight concentrations in the adenoma group and the symptomatic control group; only one patient with an adenoma had a value greater than 0·74mg/g. Wet faecal weight concentrations were increased in the adenoma group (P=0'OO3) when compared to the asymptomatic control group and five of the 10 adenoma patients had values greater than 0'35 mg/g.
DISCUSSION
Screening tests for colorectal cancer seem promising and are under intensive investigation.'? The reported sensitivities of faecal occult blood tests for colorectal cancer are very variable.P This is likely to represent differences in study design, types of faecal occult blood test, methods of application of the kit and observer variation in interpretation of colour change." The sensitivity of the faecal aI-antitrypsin test in this study was 570/0 for dry weight values compared to the symptomatic control group, and for wet weight values was 48% and 62%, respectively, in comparison with the symptomatic and asymptomatic control groups. These results are similar to the 50% suggested by a meta-analysis of international publications using Haemoccultf although individual large population studies of Haemoccult have reported higher values.P Five-day collections were undertaken in this study in order to study the relationship between transit time and faecal aI-antitrypsin, which is of importance in colorectal cancer studies. We do not envisage that 5-day collections will show significant benefit in comparison to the use of random faecal samples. The results of our study show that faecal ai-antitrypsin measurement may be of value in detecting colorectal cancer, but it will need to be compared to Haemoccult using random samples. A more convenient and inexpensive method of determining faecal aI-antitrypsin concentration is also under development.
Faecal occult blood testing has been extensively evaluated as a possible population screening test for colorectal cancer, and commonly used tests are expected to detect most cancers where blood loss is more than 20 ml/day." This degree of blood loss would be sufficient to increase faecal aI-antitrypsin to well above the upper limit of normal (given a mean serum ai-antitrypsin of 3· 5 g/U 3 and a mean wet faecal weight of 102 g/day in patients with colorectal cancer). Bleeding from colorectal cancers may be intermittent," and we propose that protein loss from colorectal cancers may also be variable. Faecal aI-antitrypsin could prove to be a more sensitive test because increased enteric protein loss may Ann Clin Biochem 1993; 30 occur due to oedema, damage to epithelial tight junctions and increased epithelial cell turnover.
Some of the symptomatic control group had potential causes of increased enteric protein loss. These patients were not excluded from the study, and had faecal aI-antitrypsin values which tended to be higher than values from those without known causes of increased protein loss. This may have reduced the apparent sensitivity of faecal alantitrypsin for colorectal cancer by raising the calculated upper limit for this control group.
Faecal aI-antitrypsin measurement was less useful for detecting colorectal adenomatous polyps < 2 em. The value of screening for adenomas is uncertain since most polyps do not develop into cancers." The detection of smaller adenomas by faecal occult bloods used in screening programmes may be serendipitous.P Faecal aI-antitrypsin values will be raised in a wide variety of conditions that cause enteric protein IOSS. 16 The specificity of this test for detecting colorectal cancer could be improved by appropriate exclusion criteria (even though it may be important to detect these other conditions). These exclusion criteria could include subjects taking non-steroidal anti-inflammatory drugs or those with significant upper gastro-intestinal symptoms or known peptic ulcer disease. Faecal occult blood tests are subject to false positive results due to dietary interference" (rather than other gastro-intestinal pathology'"). This is less common with Haemoccult, but dietary restriction remains necessary in population screening studies. Faecal occult blood tests are also subject to false negative results due to interference by degradation" and immunological tests for faecal human haemoglobin are affected similarly. The slower transit times of the cancer group would support the use of faecal tests less affected by degradation. The faecal aI-antitrypsin concentrations in our study did not correlate significantly with transit times. The measurement of faecal dicarboxylic acid porphyrins, derived from the degradation of haemoglobin, is currently being evaluated for the detection of colorectal cancer, but again this is subject to interference by dietary constituents."
The results of this study indicate that faecal alantitrypsin measurement deserves further assessment for use in detecting colorectal cancer.
